Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope Comprehensive Cancer Center
Duarte, California, United States
- Mayo Clinic in Florida
Jacksonville, Florida, United States
- Emory University Hospital/winship Cancer Institute
Atlanta, Georgia, United States
- University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
- Wayne State University/karmanos Cancer Institute
Detroit, Michigan, United States
- Mayo Clinic
Rochester, Minnesota, United States
- Hackensack University Medical Center
Hackensack, New Jersey, United States
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Dec 2015
- Primary completion
- 31 Jan 2021
- Completion
- 1 Nov 2022
- Last update posted
- 19 Sept 2024
- Registered enrollment
- 33
- Registry id
- NCT02633059
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.